13 citations
,
August 2013 in “International Journal of Dermatology” Frontal fibrosing alopecia can affect African men and may be underdiagnosed.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
7 citations
,
May 2017 in “Research and Practice in Thrombosis and Haemostasis” Some blood thinners can cause hair loss, but switching medications can stop it.
January 2016 in “Indian dermatology online journal” Frontal fibrosing alopecia causes hair loss at the front hairline, and no effective treatment exists.
9 citations
,
April 2020 in “The Journal of Urology” 5α-Reductase inhibitors don't cause depression.
November 2025 in “Journal of Investigative Dermatology” January 2024 in “Updates in clinical dermatology” Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting postmenopausal women, with unclear causes.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
April 2023 in “Journal of Dermatological Treatment” Tofacitinib helped regrow hair in a teen with a unique pattern of alopecia areata.
12 citations
,
April 2020 in “Medical hypotheses” Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
April 2021 in “Aktuelle Dermatologie” Frontal Fibrosing Alopecia is a type of hair loss that mainly affects postmenopausal women, has unclear causes, and lacks evidence-based treatments.
October 2025 in “Clinical and Experimental Dermatology” Fibrosing alopecia can be stabilized or improved with anti-inflammatory treatments and hair growth agents.
100 citations
,
November 2021 in “Cell Research” Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
September 2024 in “Cutis” Sunscreen use may increase the risk of frontal fibrosing alopecia.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
6 citations
,
January 1996 in “Endocrine-related Cancer” Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
30 citations
,
March 2011 in “Australasian Journal of Dermatology” Flutamide improves female hair loss when other treatments fail, but may cause liver toxicity.
3 citations
,
January 2022 in “Journal of The American Academy of Dermatology” Using sunscreen and moisturizers may increase the chance of developing Frontal fibrosing alopecia (FFA), but the exact reason why is still unclear.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
182 citations
,
November 2017 in “Molecular Aspects of Medicine” The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
21 citations
,
July 2014 in “Antimicrobial Agents and Chemotherapy” Finasteride effectively prevents biofilm formation and treats preformed biofilms, but requires high doses.